据比利时《回声报》报道,到2002年,全球医药市场的销售额将达4060亿美元,但市场发展很不均衡,药品的需求也趋向多样化。报道称,1998年世界三大医药公司默克、诺华和葛兰素的销售额相加约为100亿美元,仅占世界医药市场销售总额的4.2%。去年美国市场医药产品销售增长最快,增幅为11%,欧洲市场为5%,而日本市场则下降1%。由于美国政府对药品市场的干预少,对新药还给予政府补贴,药品价格由企业自主制订,美国医药市场的潜力巨大。而欧洲各国由于实行社会保障体系,政府为降低医药费用负担,往往对药品价格实行监督检查制度。近年来,美国医药行业的兼并势头强劲,这对于进入美国市场的企业十分有利。因为美国式的兼并其目的往往在于拓展市场,应付未来的种种挑战。随着兼并后企业规模的扩大,对研究发展费用的投入 According to the Belgian “Echo News” report, by 2002, the global pharmaceutical market sales will reach 406 billion US dollars, but the market development is very uneven, the demand for drugs also tend to diversify. Reported that in 1998 the world’s three major pharmaceutical companies Merck, Novartis and Glaxo’s sales add about 10 billion US dollars, accounting for only 4.2% of the total world pharmaceutical market sales. Last year, the sales growth of pharmaceutical products in the United States market was the fastest, with an increase of 11%. The European market was 5%, while the Japanese market decreased by 1%. Because the U.S. government has little intervention in the drug market, it also gives government subsidies for new drugs. The prices of drugs are set by enterprises themselves, and the U.S. pharmaceutical market has great potential. In Europe, due to the implementation of the social security system, the government often implements a supervision and inspection system for drug prices in order to reduce the burden of medical expenses. In recent years, the US pharmaceutical industry has seen a strong momentum of mergers and acquisitions, which is very beneficial to companies entering the US market. Because the purpose of American-style mergers and acquisitions is often to expand markets and meet future challenges. With the expansion of the size of the enterprise after the merger, investment in research and development costs